Table 1.
Parameters | Value |
---|---|
Number | 34 |
Gender (male/female) | 12/22 |
Age at diagnosis | 61.7 ± 11.9 |
MPO-ANCA/PR3-ANCA | 30/4 |
ESR (mm/1 h) | 65.8 ± 39.2 |
Scr (μmol/L) | 266.9 (196.3–410.0) |
Proteinuria (g/24 h) | 1.42 ± 1.25 |
Clinical manifestation | |
Skin rash | 5 (14.7%) |
Arthralgia | 3 (8.8%) |
Muscle pain | 5 (14.7%) |
Pulmonary | 18 (52.9%) |
ENT | 10 (29.4%) |
Ophthalmic | 10 (29.4%) |
Gastrointestinal | 3 (8.8%) |
Nervous | 5 (14.7%) |
BVAS | 18.6 ± 5.2 |
Glomeruli per biopsy | 30.0 ± 13.8 |
Glomerular lesions (%) | |
Total crescents | 62.2 ± 21.0 |
Fibrinoid necrosis | 1.3 (0–6.6) |
Glomerulosclerosis | 2.7 (0–10.0) |
Tubulointerstitial lesions | |
Tubular atrophy (−/+/++) | 5/25/4 |
Interstitial infiltration (−/+/++/+++ ) | 0/8/21/5 |
Interstitial fibrosis (−/+/++) | 3/25/6 |
Berden classification n (%) | |
Focal | 5 (14.7) |
Crescentic | 24 (70.6) |
Mixed | 5 (14.7) |
Sclerotic | 0 (0) |
Statistics are shown as mean ± standard deviation or median (IQR) for different distributions
ESR erythrocyte sedimentation rate, Scr serum creatinine, ENT ear, nose and throat, BVAS Birmingham Vasculitis Activity Score